Caligan Partners as of June 30, 2024
Portfolio Holdings for Caligan Partners
Caligan Partners holds 13 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 29.0 | $124M | 10M | 12.00 | |
| Alimera Sciences Com New | 21.9 | $94M | 17M | 5.56 | |
| Anika Therapeutics (ANIK) | 8.5 | $36M | 1.4M | 25.33 | |
| Exelixis (EXEL) | 8.0 | $34M | 1.5M | 22.47 | |
| BioCryst Pharmaceuticals (BCRX) | 6.6 | $28M | 4.6M | 6.18 | |
| Verona Pharma Sponsored Ads (VRNA) | 6.2 | $27M | 1.8M | 14.46 | |
| Evolus (EOLS) | 5.5 | $24M | 2.2M | 10.85 | |
| Agios Pharmaceuticals (AGIO) | 5.2 | $22M | 515k | 43.12 | |
| Enanta Pharmaceuticals (ENTA) | 3.2 | $14M | 1.0M | 12.97 | |
| Mineralys Therapeutics (MLYS) | 2.0 | $8.7M | 746k | 11.70 | |
| Y Mabs Therapeutics | 1.6 | $7.0M | 582k | 12.08 | |
| I Mab Sponsored Ads (IMAB) | 1.3 | $5.6M | 3.4M | 1.67 | |
| Outlook Therapeutics (OTLK) | 0.9 | $3.7M | 500k | 7.38 |
